R&D at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Baxter International's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Baxter International's R&D?
- Baxter International (BAX) reported R&D of $139M in Q1 2026.
- How has Baxter International's R&D changed year-over-year?
- Baxter International's R&D decreased by 0.7% year-over-year, from $140M to $139M.
- What is the long-term trend for Baxter International's R&D?
- Over 4 years (2021 to 2025), Baxter International's R&D has grown at a -0.6% compound annual growth rate (CAGR), from $531M to $518M.
- What does R&D mean?
- Spending on the development of new products and the improvement of existing ones.
- How do you interpret R&D?
- Consistent or increasing R&D spend is generally positive for long-term growth, whereas significant cuts may signal a focus on short-term profitability at the expense of future innovation.
- How does R&D compare across companies?
- Highly comparable within the healthcare sector; peers with higher R&D intensity often command higher valuations due to innovation potential.